K. K. Ray Et Al. , "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial," LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8, pp.618-628, 2019
Ray, K. K. Et Al. 2019. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8 , 618-628.
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., ... Budaj, A. J.(2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8, 618-628.
Ray, Kausik Et Al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial," LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8, 618-628, 2019
Ray, Kausik K. Et Al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8, pp.618-628, 2019
Ray, K. K. Et Al. (2019) . "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." LANCET DIABETES & ENDOCRINOLOGY , vol.7, no.8, pp.618-628.
@article{article, author={Kausik K. Ray Et Al. }, title={Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial}, journal={LANCET DIABETES & ENDOCRINOLOGY}, year=2019, pages={618-628} }